Can-Fite Reports First Quarter 2015 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Can-Fite Reports First Quarter 2015 Results

Can-Fite BioPharma (CANF) Reports Q1 EPS of NIS0.06

May 29, 2015 7:02 AM EDT

Can-Fite BioPharma (NYSE: CANF) reported Q1 EPS of NIS0.06, versus NIS0.37 reported last year.

Clinical Development Program and Corporate Highlights Include:

CF101 Finalizing Design for Next Advanced Clinical Studies Can-Fite completed the design of a Phase III clinical study for the treatment of patients with rheumatoid arthritis. The Phase III design is based on positive data received from the Company's completed Phase IIb study in which CF101 was administered as a monotherapy. Can-Fite plans on submitting the Phase III study protocol to Institutional Review Boards (IRBs) for... More